Dopamine and depression: Therapeutic implications

CNS Drugs

Volumn 13, Issue 1, 2000, Pages 35-45

  Rampello, Liborio ^a   Nicoletti, Ferdinando ^a,b   Nicoletti, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMINEPTINE; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADAPTATION; DEPRESSION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; REVIEW;

EID: 0033983993     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013010-00004     Document Type: Review

References (83)

1. 1. Randrup, A, Munkvad I, Fog R, et al. Mania, depression, and brain dopamine. In: Essman WB, Valzelli L, editors. Current development in psychopharmacology. New York (NY): Spectrum Publications, 1975: 207-29
2. 2. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32: 1-17
3. 3. Pepeschi R, McClure DJ. Homovanillic and 5-hydroxyindoloacetic acid in cerebrospinal fluid of depressed patients. Arch Gen Psychiatry 1971; 25: 354-8
4. 4. Goodwin FK, Post RM, Dunner DL, et al. Cerebrospinal fluid amine metabolites in affective illness. The probenecid technique. Am J Psychiatry 1973; 130: 73-9
5. 5. Jimerson DC. Role of dopamine mechanisms in the affective disorders. In: Meltzer HY, editor. Psychopharmacology: the third generation of progress. New York (NY): Raven Press, 1987:505-11
6. 6. Vestergaard P, Sorensen T, Hoppe E, et al. Biogenic amine metabolites in cerebrospinal fluid of patients with affective disorders. Acta Psychiatr Scand 1978; 58: 88-96
7. 7. Commings JL. Psychosomatic aspects of movement disorders. Adv Psychosom Med 1985; 13: 111-32
8. 8. Mayeux R. Parkinson's disease. J Clin Psychiatry 1990; 51: 20-3
9. 9. Goodwin FK, Sack RL. Central dopamine function in affective illness: evidence from precursors, enzyme inhibitors, and studies of central dopamine turnover. In: Usdin E, editor. Neuropsychopharmacology of monoamines and their regulatory enzymes. New York (NY): Raven Press, 1974: 261-77
10. 10. McKinney WT, Kane FJ. Depression with the use of alpha-methyldopa. Am J Psychiatry 1967; 124: 118-9
11. 11. Willner P. Dopamine and depression: a review of recent evidence. II. Theoretical approaches. Brain Res 1983; 287 (3): 225-36
12. 12. Raskin A, Schulterhrandt JG, Reatig N, et al. Differential response to chlorpromazine, imipramine, and placebo. Arch Gen Psychiatry 1970; 23: 164-72
13. 13. Raskin A, Crook TH. The endogenous-neurotic distinction as a predictor of response to antidepressant drugs. Psychol Med 1976; 6: 59-70
14. 14. Sherman AD, Sacquitine IL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982; 16: 449-54
15. 15. Anisman H, Remington G, Sklar LS. Deficits of escape performance following catecholamine depletion: implications for behavioural deficits induced by uncontrollable stress. Psychopharmacology 1979; 64: 163-70
16. 16. Anisman H, Remington G, Sklar LS. Effect of inescapable shock on subsequent escape performance: catecholamine and cholinergic mediation of response initiation and maintenance. Psychopharmacology 1979; 61: 107-24
17. 17. Borsini F, Meli A. The forced swimming test: its contribution to the understanding of the mechanism of action of antidepressant drugs. In: Gessa GL, Serra G, editors. Dopamine and mental depression. Oxford: Pergamon Press, 1990: 63-76
18. 18. Koob GF. Drug addiction: the yin and yang of hedonic homeostasis. Neuron 1996; 16: 893-6
19. 19. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely-moving rats. Proc Natl Acad Sci USA 1988; 85: 5274-8
20. 20. Einhorn LC, Johansen PA, White FJ. Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: studies in the ventral tegmental area. J Neurosci 1988; 8: 100-12
21. 21. Uchimura N, North RA. Actions of cocaine on rat nucleus accumhens neurones in vitro. Br J Pharmacol 1990; 99: 736-40
22. 22. Hyman SE. Addiction to cocaine and amphetamine. Neuron 1996; 16: 901-4
23. 23. Nestler EJ. Under siege: the brain of opiates. Neuron 1996; 16: 897-900
24. 24. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905-8
25. 25. Tabakoff B, Hoffman PL. Alcohol addiction: an enigma among us. Neuron 1996; 16:909-12
26. 26. Yadid G, Pacak K. Kopin I-J, et al. Endogenous serotonin stimulates striatal dopamine release in conscious rats. J Pharmacol Exp Ther 1994; 270: 1158-65
27. 27. West AR, Galloway MP. Regulation of serotonin-facilitated dopamine release in vivo. The role of protein kinase A activating transduction mechanisms. Synapse 1996; 23: 20-7
28. 28. Morrow B-A, Roth RH. Serotonergic lesions after cocaine-induced locomotor behaviour and stress activation of the mesocorticolimbic dopamine system. Synapse 1996; 23: 1174-8
29. 29. De Deuwaerdere P, Bonhomme N, Lucas G, et al. Serotonin enhances striatal dopamine outflow in vivo through dopamine uptake sites. J Neurochem 1996; 66: 210-5
30. 30. Kay S, Marburger A, Reum T, et al. 5,7-Dihydroxytryptamine lesions of the median or dorsal raphe nucleus reduce striatal high affinity dopamine uptake in rats [abstract no. 48.2]. 28th Annual Meeting of the Society for Neuroscience (SNF): 1998 Nov 7-12: Los Angeles, CA
31. 31. Spampinato U, De Deuwaerdere P, Caccia S, et al. Opposite role of central 5-HT2a and 5-HT2c receptor subtypes in the control of haloperidol-induced release of dopamine in the rat striatum [abstract no. 48.6]. 28th Annual Meeting for the Society for Neuroscicnce (SNF): 1998 Nov 7-12: Los Angeles, CA
32. 32. Ketter TA, Jenkins JB, Schroeder DH, et al. Carbamazepine, but not valproate induces bupropion metabolism. J Clin Psychopharmacol 1995 Oct; 15 (5): 327-33
33. 33. Sweet RA, Pollock BG, Kirshner M, et al. Pharmacokinetics of single and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995 Sep; 35 (9): 866-84
34. 34. Rush CR, Kollins SH, Pazzaglia PJ. Discriminative stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 1998 Feb; 6(1): 32-44
35. 35. Nomikos GG, Damsma G, Wenkstern D, et al. In vivo characterisation of locally applied dopamine uptake inhibitors by striatil microdialysis. Synapse 1990; 6: 106-12
36. 36. Nomikos GG, Damsma G, Wenkstern D, et al. Effects of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacol 1992; 7: 7-14
37. 37. Ascher JA, Cole JO, Colin J-N, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 1995 Sep; 56 (9): 395-402
38. 38. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997 Dec; 58 (12): 532-7
39. 39. Roland DL, Myers L, Culver A, et al. Bupropion and sexual function: a placebo controlled prospective study on diabetic men with erectile dysfunction. J Clin Psychopharmacol 1997 Oct; 17 (5); 350-7
40. 40. Ferguson J, Cunningham L, Merideth C, et al. Bupropion in tricyclic antideprcssant nonresponders with unipolar major depressive disorder. Ann Clin Psychiatry 1994 Sep; 6 (3): 153-60
41. 41. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994 Jun; 14 (3): 170-9
42. 42. Pearlstein TB, Stone AB, Lund SA, et al. Comparison of fluoxetine, bupropion and placebo in the treatment of premenstrual dysphoric disorder. J Clin Psychopharmacol 1997 Aug; 17 (4): 261-6
43. 43. Connesrs CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996 Oct; 35 (10): 1314-21
44. 44. Barrickman LL, Perry PJ, Allen AJ, et al. Bupropion versus methylphenydate in the treatment of attention deficit hyper-activity disorder. J Am Acad Child Adolesc Psychiatry 1995 May; 34 (5): 649-57
45. 45. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994 Sep; 55 (9): 391-3
46. 46. Hsyu PH, Singh A, Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus non-smokers. J Clin Pharmacol 1997 Aug; 37 (8): 737-43
47. 47. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained release bupropion and placebo for smoking cessation. N Eng J Med 1997 Oct; 337 (17): 1195-202
48. 48. Amore M, Giordani L, Giorgetti G, et al. Pharmacological treatment of delusional depression. Minerva Psichiatr 1996 Mar; 37 (1): 29-33
49. 49. Physicians desk reference. 53rd ed. Montvale (NJ): Medical Economics Co., 1999
50. 50. Garattini S. Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system; a review. Int Clin Psychopharmacol 1997 Jul; 12 Suppl. 3: SI5-9
51. 51. Blayac JP, Hillaire-Buys D, Peyrière H. Pharmacovigilance of new antidepressants: evaluation of neuro-psychobehavioural disorders [in French]. Therapie 1997 Mar; 52 (2): 117-22
52. 52. Prescrire welcomes amineptine withdrawal. SCRIP 1999 Feb 10; 2410: 23
53. 53. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 1997 Jul; 12 Suppl. 3: S7-14
54. 54. Freeman H. Early onset of action of amineptine. Int Clin Psychopharmacol 1997 Jul; 12 Suppl. 3: S29-33
55. 55. Dalery J, Rochat C, Peyron E, et al. The efficacy and acceptability of amineptine versus fluoxetine in major depression. Int Clin Psychopharmacol 1997 Jul; 12 Suppl. 3; S35-8
56. 56. Ferreri M, Colonna L, Leger JM. Efficacy of amineptine in the prevention of relapse in unipolar depression. Int Clin Psychopharmacol 1997 Jul; 12 Suppl. 3: S39-45
57. 57. Rampello L, Nicoletti G, Raffaele R, Dopaminergic hypothesis for retarded depression: a symptom profile for predicting therapeutical responses. Acta Psychiatr Scand 1991; 84: 552-4
58. 58. Montejo AI, Llorca G, Izquierdo JA, et al. Sexual dysfunction secondary to SSRIs. A comparative analysis in 308 patients [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1996 Nov; 24 (6): 311-21
59. 59. Montejo-Gonzàles AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicentric, and descriptive clinical study of 344 patients. J Sex Marital Ther 1997 Feb; 23 (3): 176-94
60. 60. Jittiwutikan J, Srisurapanont M, Jarasuraisin N. Amineptine in the treatment of amphetamine withdrawal: a placebo controlled, randomised, double-blind study. J Med Assoc Thai 1997 Sep; 80 (9): 587-92
61. 61. Rampello L, Nicoletti G, Raffaele R. Comparative effects of amitriptyline and amineptine in patients affected by anxious depression. Neuropsychobiol 1995; 31: 130-4
62. 62. Fromently B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997; 26 Suppl. 2: 43-53
63. 63. Lonardo A, Grisendi A, Mazzone E. One more case of hepatic injury due to amineptine. Ital J Gastroenterol Hepatol 1997 Dec; 29 (6): 580-1
64. 64. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996 Feb; 24 (2): 200-8
65. 65. Larrey D, Pageaux GP. Genetic predisposition to drug-induced hepatotoxicity. J Hepatol 1997; 26 Suppl. 2: 12-21
66. 66. Ferretti P, Alger S, Benfenati F, et al. Chemical effects of minaprine on striatal dopaminergic neurons in rats. J Pharmacol 1984; 36: 48-50
67. 67. Biziere K, Gueudut C, Kan IP, et al. Atypical dopaminergic profile of minaprine: a new antidepressant drug. Br J Pharmacol 1984; 81: 51-3
68. 68. Edwards JG, Dinan TG, Waller DG, et al. Double-Wind comparative study of the antidepressant, unwanted and cardiac effects of minaprine and amitriptyline. Br J Clin Pharmacol 1996 Oct; 42 (4): 491-8
69. 69. Barlocco D, Cignarella G, Fanelli F, et al. Thienocycloheptapyridazines as new muscarinic agents. Drug Des Discov 1997 Apr; 14 (4): 273-90
70. 70. Allain H, Belliard S, Lieury A, et al. Randomised double blind comparative study of minaprine (200 mg/j) and of placebo on memory loss. Therapie 1996 Mar; 51 (2): 155-62
71. 71. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83-97
72. 72. Dufour A, Desanti C. Amisulpride: pharmacocinètique et métabolisme. Ann Psychiatr 1988; 3: 298-305
73. 73. Bellino S, Burzega G, Bogetto F, et al. An open-label, randomised, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly. Curr Ther Res Clin Exp 1997; 58: 798-808
74. 74. Rein W, Ayuso JL. Amisulpride expert report on clinical documentation (dysthymia). Le Plessis-Robinson: Synthelabo Group. In press
75. 75. Fielding S, Szewczak MR. Pharmacology of nomifensine: a review of animal studies. J Clin Psychiat 1984; 45 (4): 12-20
76. 76. Ebert D, Berger M. Neurobiological similarities in antidepressant sleep deprivation and psychostimulant use: a psychostimulant theory of antidepressant sleep deprivation. Psychopharmacology 1998; 140: 1-10
77. 77. Ebmeier KP, Ebert D. Imaging functional change and dopaminergic activity in depression. In: Beninger R, Palomo T, Archer T, editors. Dopamine disease states. Madrid: CYM, 1996: 511-22
78. 78. D'haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with SPECT. Biol Psychiatry 1994; 35: 128-32
79. 79. Shaw PJ, Ogilvie A, Goodwin GM, et al. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 1998; 131: 18-26
80. 80. Ebert D, Albert R, Hammond R, et al. Eye-blink rates and depression. Is the antidepressant effect of sleep deprivation mediated by the dopamine system? Neuropsychopharmacology 1996; 15 (4): 332-9
81. 81. Ebert D, Feistel H, Barocka A, et al. SPECT assessment of cerebral dopamine D2 receptor blockade in depression before and after sleep deprivation. Biol Psychiatry 1994; 35: 880-5
82. 82. Laruelle E. SPECT imaging of striatal dopamine release after amphetamine. J Nucl Med 1995; 36: 1182-90
83. 83. Lammers CH, Duaz G, Levesque D, et al. Regulation of dopaminergic receptor mRNA by antidepressants [abstract]. Pharmacopsychiatry 1995; 28: 196